Draegerwerk AG & Co. KGaA AI Stock Analysis
Want to see DE:DRW8 full AI Analyst Report?
Draegerwerk AG & Co. KGaA (DRW8) AI Stock Analysis
Draegerwerk AG & Co. KGaA
(XETRA:DRW8)
Dräger scores well on fundamentals and valuation. The standout strength is an exceptionally conservative balance sheet — low debt, rising equity and over half of assets equity-funded — combined with three years of margin repair and a sharp rebound in cash flow. At a P/E of 11.2 with a near 3% dividend yield, the shares look inexpensive, and the latest earnings call confirmed guidance while highlighting improving order intake, a stronger Safety division, defence growth potential and the removal of the FDA warning letter. The main offsets are weak near-term technicals — the price sits below its 20-, 50- and 100-day averages with a negative MACD — alongside structurally thin margins, a still loss-making Medical division, rising functional expenses and soft demand in China and the Americas.
Draegerwerk AG & Co. KGaA (DRW8) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 1.59B
- Dividend Yield
- 2.48%
- Average Volume (3M)
- 4,046
- Price to Earnings (P/E)
- 12.8
- Beta (1Y)
- 0.67
- Revenue Growth
- 5.06%
- EPS Growth
- 40.18%
- Country
- Germany
- Employees
- 16,687
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Draegerwerk AG & Co. KGaA Business Overview & Revenue Model
Company Description
Headquartered in Lübeck, Germany, and established in 1889, Drägerwerk AG & Co. KGaA is an international enterprise specializing in medical and safety technology, with operations spanning Europe, the Americas, Africa, Asia, and Australia. For the heal...
How the Company Makes Money
Dräger generates revenue primarily through the sale of equipment, consumables/accessories tied to its installed base, and recurring service and maintenance offerings across its Medical and Safety segments. 1) Product/equipment sales (often higher-tic...
Draegerwerk AG & Co. KGaA Earnings Call Summary
The call was predominantly positive. Dräger reported strong nine-month order intake, sales, earnings, cash flow, balance-sheet improvement and Safety division momentum, confirmed full-year guidance, and highlighted the lifting of the FDA warning letter and opportunities in defense. These positives were tempered by third-quarter EBIT and Medical performance declines, higher functional expenses, a negative net tariff effect, weaker China demand, Americas and APAC pressure in specific areas, and the need for tight fourth-quarter cost management.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For the full year of 2026, Dräger confirmed guidance for net sales growth of 2% to 6%, net of currency effects, and an EBIT margin of 6% to 8%; the target remains unchanged to keep full year expense growth below net sales growth, free cash flow is expected to continue to develop positively, and the company expects order intake and sales to be better for the remainder of the year, with the fourth quarter being the best quarter. The goal to increase defense business from roughly EUR 100 million, which was had in around '25, to around EUR 300 million is unchanged, and the dividend policy remains unchanged at distributing at least 30% of net income as dividend.
Draegerwerk AG & Co. KGaA Financial Statement Overview
Summary
Dräger combines a fortress balance sheet (Score 82) with improving cash generation (Score 74) and a steady earnings recovery (Score 68). Debt has fallen to €228.9 million against €1.71 billion of equity (debt/equity of 0.23), equity funds roughly 52% of assets, operating cash flow reached €320.5 million TTM and free cash flow €227.4 million. Margins have expanded consistently — gross margin to 46.0%, operating margin to 7.7% and net margin to 4.8% — lifting net income to €169.6 million. Offsetting this are structurally thin profitability for a medical device business, low-single-digit revenue growth, moderate 10.6% return on equity, and a track record of volatility, including the 2022 loss year and negative free cash flow.
Income Statement
68PositiveBalance Sheet
82Very PositiveCash Flow
74Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.59B | 3.48B | 3.37B | 3.37B | 3.05B | 3.33B |
| Gross Profit | 1.67B | 1.52B | 1.51B | 1.46B | 1.24B | 1.54B |
| EBITDA | 404.63M | 384.83M | 351.68M | 318.33M | 62.63M | 421.65M |
| Net Income | 169.59M | 139.50M | 124.41M | 110.43M | -64.56M | 154.23M |
Balance Sheet | ||||||
| Total Assets | 3.26B | 3.28B | 3.09B | 3.09B | 3.11B | 3.18B |
| Cash, Cash Equivalents and Short-Term Investments | 270.90M | 284.06M | 248.18M | 279.36M | 319.50M | 577.38M |
| Total Debt | 228.93M | 405.11M | 395.58M | 471.38M | 361.95M | 348.01M |
| Total Liabilities | 1.55B | 1.65B | 1.56B | 1.69B | 1.79B | 1.92B |
| Stockholders Equity | 1.71B | 1.63B | 1.54B | 1.41B | 1.32B | 1.26B |
Cash Flow | ||||||
| Free Cash Flow | 227.35M | 166.50M | 103.52M | 121.47M | -231.09M | 274.54M |
| Operating Cash Flow | 320.54M | 238.33M | 167.31M | 189.68M | -144.23M | 384.89M |
| Investing Cash Flow | -82.54M | -98.15M | -43.39M | -67.34M | 36.83M | -109.92M |
| Financing Cash Flow | -162.12M | -83.99M | -161.38M | -154.56M | -29.38M | -334.64M |
Draegerwerk AG & Co. KGaA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:DRW8, the sentiment is Positive. The current price of 89.00 is above the 20-day moving average (MA) of 78.32, above the 50-day MA of 82.95, and above the 200-day MA of 75.57, indicating a bullish trend. The MACD of 1.17 indicates Negative momentum. The RSI at 66.30 is Neutral, neither overbought nor oversold. The STOCH value of 82.14 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:DRW8.
Draegerwerk AG & Co. KGaA Peers Comparison
Overall Rating
DE:EUZ80Outperform
DE:SHL77Outperform
DE:AFX73Outperform
DE:DRW870Outperform
DE:M3V55Neutral
DE:SBS54Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | EUR 922.97M | 16.95 | 20.26% | 1.49% | 4.05% | 36.66% | |
| 77Outperform | EUR 48.89B | 22.13 | 11.72% | 2.28% | 1.09% | 3.52% | |
| 73Outperform | EUR 2.89B | 19.32 | 5.52% | 1.70% | -0.06% | -38.81% | |
| 70Outperform | EUR 1.90B | 12.83 | 10.20% | 2.48% | 5.06% | 40.18% | |
| 55Neutral | EUR 38.95M | 28.16 | 7.77% | 4.44% | -6.92% | -67.82% | |
| 54Neutral | EUR 347.66M | -8.19 | -18.69% | 2.10% | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:DRW8 | Draegerwerk AG & Co. KGaA (0MT8) | 89.00 | 30.25 | 51.49% | |
| DE:AFX | Carl Zeiss Meditec | 32.26 | -10.15 | -23.93% | |
| DE:EUZ | Eckert & Ziegler Strahlen und Medizintechnik | 14.75 | -0.50 | -3.29% | |
| DE:M3V | MeVis Medical Solutions | 21.40 | -2.50 | -10.46% | |
| DE:SBS | STRATEC Biomedical | 28.60 | 9.08 | 46.48% | |
| DE:SHL | Siemens Healthineers | 43.82 | 3.03 | 7.43% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026
